AMBALALSAAmbalal Sarabhai Enterprises Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures, markets, and supplies pharmaceutical products in India and internationally. The company offers products for oncology, infertility, and uro-gynaec areas; generic and veterinary products; antifungal active ingredient products; vitamin C coated products; and analytical, test, and measuring instruments, as well as supplies finished dosage forms and active pharmaceutical ingredients. It also provides broadcast and professional video/audio, and electronic products. Ambalal Sarabhai Enterprises Limited was incorporated in 1977 and is based in Ahmedabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on AMBALALSA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 30/100)
- • Revenue growth: 8.0% YoY
- • Profit growth: -51.4% YoY
- • RSI: 37
- • MACD: bearish
Bull case
- • Debt/Equity: 0.36
- • Valuation vs sector: P/E 20.9 vs sector 35.5
- • 3-month return: +9.8%
- • 3-month vs NIFTY: +14.1% relative
Bear case
- • Revenue growth: 8.0% YoY
- • Profit growth: -51.4% YoY
- • RSI: 37
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Revenue growth: 8.0% YoY
- • Profit growth: -51.4% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹1.91). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.